Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hansa Biopharma enters into collaboration with Genethon
The partnership, in a clinical trial, will assess the efficacy and safety of imlifidase, Hansa Biopharma’s antibody cleaving enzyme, as a pre-treatment prior to the administration of Genethon’s
The partnership, in a clinical trial, will assess the efficacy and safety of imlifidase, Hansa Biopharma’s antibody cleaving enzyme, as a pre-treatment prior to the administration of Genethon’s
Opfolda will be used as an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in LOPD (acid α glucosidase [GAA] deficiency) adult patients. The European Commission (EC)
Under the terms of the deal, Stablix will use its platform to discover new heterobifunctional small molecule drug candidates (RESTORACs) against specified targets which are involved in several
The company has invested €350m in the new research and development (R&D) centre, representing its largest single investment in the country to date. The new high-tech facility will
Known as DERMAdoctor Comfort + Joy Psoriasis Therapeutic Moisturizing Cream with 3% salicylic acid, the product will be introduced on the QVC network. The new cream will be
This partnership will focus on exploring joint venture (JV) opportunities for advancing a Phase II ready asset and the preclinical prodrug asset of BullFrog AI. The Phase II
Currently, the company has six fill finish lines in San Diego, US, that includes a new line which provides various configurations, such as vials, cartridges, and prefilled syringes.
A first-in-class, phosphate absorption inhibitor, Xphozah will be used to control serum phosphate in adults with chronic kidney disease (CKD) on dialysis and who had an insufficient response
This therapy helps to pace up the recovery of neutrophils (a subset of white blood cells) in the body and lower risk infection. Omisirge is intended for use
Sweden-based Abliva has announced that its drug candidate NV354 has been received orphan drug designation (ODD) from the US FDA Office of Orphan Products Development to treat mitochondrial